Washington D.C., DC Clinical Trials Report — June 2026

For residents of Washington D.C., June 2026 presents both urgent opportunities and significant new avenues to participate in clinical research. A total of 51 clinical trials are slated to conclude enrollment within the next 90 days, making prompt action essential for those interested in joining these studies. This urgency is particularly relevant for healthy volunteers, as 5 of these rapidly closing studies are still actively seeking participants without specific health conditions.

Act Now: Trials Nearing Enrollment Deadlines

Patients managing specific health conditions also have limited time to join research before enrollment closes. Trials focused on various cardiovascular issues, neurological conditions, and other health challenges are among those with impending deadlines:

• Aortic valve insufficiency (2 trials)
• Cancer (2 trials)
• HIV (2 trials)
• Urea cycle disorder (2 trials)
• Spinal cord injuries (2 trials)
• Aortic regurgitation (2 trials)
• Aortic insufficiency (2 trials)
• Bias, racial (1 trial)
• Aortic valve disease (1 trial)
• Adult congenital heart disease (1 trial)

These studies offer a critical chance to contribute to medical advancements in these areas before their enrollment windows close.

New Research Opportunities Emerge in Washington D.C.

Washington D.C. saw a notable increase in new research this month, with 13 new clinical trials opening for enrollment. This marks a significant rise from the 7 trials that launched in May 2026, indicating a growing research landscape. Overall, 818 clinical trials are currently recruiting across 286 research facilities in the city.

June brings several high-profile new trials to Washington D.C., including a significant Phase 3 study from a major sponsor. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic approaches across a range of health challenges.

• Novo Nordisk A/S is sponsoring a notable Phase 3 study, NCT07668414, "A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide." This trial aims to determine if zenagamtide is safe and effective for treating participants with excess body weight, comparing it to semaglutide. This study seeks 650 participants.
• Vanderbilt University Medical Center is leading NCT07674758, "Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials." This research aims to better understand the evolution of heart dysfunction in patients with Duchenne and Becker Muscular Dystrophy (DMD/BMD) and carriers, which is a leading cause of death. This study plans for 1,000 participants.
• International Food Policy Research Institute is sponsoring NCT07640594, "Randomized Evaluation of Voucher Interventions for Value and Effectiveness (REVIVE) in Philippines." This behavioral study aims to evaluate whether revised food voucher programs combined with nutrition education can improve food security, dietary quality, and nutritional outcomes among low-income households. It targets 5,320 participants.
• Montefiore Medical Center is initiating NCT07631598, "Buprenorphine Implementation at Syringe Service Programs to Reduce Overdoses." This study investigates if offering buprenorphine treatment directly at syringe service programs (SSPs) is more effective for opioid use disorder (OUD) treatment than traditional referrals. This study seeks 512 participants.
• Georgetown University is sponsoring NCT07618520, "Expanding Genetic Access for Prostate Cancer Survivors." The goal of this study is to increase genetic education and testing for hereditary cancer risk among prostate cancer survivors by testing the effectiveness of different digital and print guides. This study plans for 500 participants.
• AngioInsight is leading NCT07676097, "Simultaneous Measurement of EpicArdial and Microvascular ResisTance Via Angiographic FLOW Study." This observational study aims to establish the diagnostic performance of the AngioAI+ System for estimating fractional flow reserve (FFR) and detecting coronary microvascular disease (CMD). This study seeks 620 participants.

New trials this month are exploring a range of conditions, including becker muscular dystrophy, brain tumor, cardiovascular disease, cardiomyopathy, and duchenne muscular dystrophy. Behavioral trials account for the largest share of new studies with 6 new trials, followed by 4 drug trials and 2 radiation trials.

Opportunities for Healthy Volunteers

For individuals without a specific medical condition, there are significant opportunities to contribute to research. Of the 13 new trials launched this month, 3 are actively seeking healthy volunteers. Across Washington D.C., a total of 92 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Washington D.C.'s Leading Research Facilities

Washington D.C. is home to several prominent research institutions that consistently conduct a high volume of clinical trials. These facilities are key destinations for individuals seeking to participate in medical research:

• Children's National Medical Center (97 trials)
• MedStar Washington Hospital Center (67 trials)
• MedStar Georgetown University Hospital (65 trials)
• Children's National Hospital (65 trials)
• Sibley Memorial Hospital (44 trials)
• Georgetown University Medical Center (33 trials)
• Georgetown University (33 trials)
• Research Site (25 trials)
• George Washington University Medical Center (21 trials)
• George Washington University (19 trials)

These institutions offer a broad spectrum of research, from pediatric care at Children's National Medical Center and Children's National Hospital, to diverse medical fields at MedStar Washington Hospital Center, MedStar Georgetown University Hospital, and the George Washington University facilities.

Diverse Participation and Local Research Landscape

Participation in clinical trials is open to a diverse range of individuals. Of the 13 new trials launched this month, 11 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 2 new trials include children, and 3 are male-only. Academic institutions continue to play a vital role in Washington D.C.'s research ecosystem, with Georgetown University (4 trials) and George Washington University (2 trials) sponsoring the most new studies this month. Industry sponsors like Novo Nordisk A/S (1 trial) are also driving significant research efforts.

There are currently no other nearby cities in the District of Columbia with active trials to broaden your search.

As we move through June, Washington D.C.'s dynamic research community will continue to drive medical innovation, offering diverse opportunities for individuals to contribute to the future of healthcare and health policy.